Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor

Study Identifier
M25-850
CT.gov Identifier
NCT07673107
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Recruiting
Sign up for trial alerts

Study Details

Medical Condition
  • Unmapped
    • Study Drug
  • AGN-151607-DP
  • Placebo for AGN-151607-DP
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18 - 85 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Minimum body weight of 50 kg (110 pounds) at Screening. * Diagnosis of essential tremor (ET) in accordance with the modified Tremor Research Investigation Group (TRIG) criteria, as follows: * Bilateral postural tremor with or without kinetic tremor, involving hands and forearms * Tremor of other body parts may or may not be present in addition to upper limb (UL) tremor * Bilateral tremor may or may not be asymmetric * Tremor that is reported by the participant to be persistent, although the amplitude may fluctuate.
    Exclusion Criteria:
    * History of any medical condition that may put the participant at increased risk with exposure to purified botulinum toxin type A complex, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other significant disease that might interfere with neuromuscular junctional disorders. * History of an allergic reaction to or significant sensitivity to AGN-151607-DP or its excipients and/or other botulinum toxins.

    Protocol Summary

    Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET.

    AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada.

    Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks.

    The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.

    Study Locations

    Location
    Status
    Location
    Neuro Pain Research Center /ID# 277899
    Fresno, California, United States, 93710
    Status
    Recruiting
    Location
    Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079
    Boca Raton, Florida, United States, 33486
    Status
    Recruiting
    Location
    Charter Research - Winter Park /ID# 277875
    Orlando, Florida, United States, 32803-1839
    Status
    Recruiting